We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Sunflower Protein May Help Block Tumor Spread in Prostate Cancer

By Biotechdaily staff writers
Posted on 27 May 2008
A mini-protein found in sunflower seeds could be the key to stopping tumors spreading in prostate cancer patients, according to Australian researchers. More...


Dr. Jonathan Harris, a senior lecturer in Queensland University of Technology's (QUIT; Brisbane, Australia) Faculty of Science, and Ph.D. student Joakim Swedberg, from both the University's Institute of Health and from Biomedical Innovation, are working on the naturally occurring molecule.

"We are interested in this miniprotein as a potential treatment of prostate cancer, in particular for those patients who relapse,” said Dr Harris. "We are interested in this miniprotein as a potential treatment of prostate cancer, in particular for those patients who relapse. The best thing to do in those cases is block the disease spreading to other organs, particularly the spine, which is very debilitating; it is not the prostate tumor that kills you, it is when the cancer cells escape from the prostate so we want to prevent that.”

Another QUT researcher, Prof. Judith Clements, had previously demonstrated that the action of enzymes called proteases was a critical process in metastasis, and Dr. Harris reported that the sunflower mini-protein, known as the protease inhibitor, was able to block these enzymes in test tube-based assays.

"However, it also inhibits a whole range of proteases, some of which control important processes in the body, so we have re-engineered the molecule so it should just block the proteases produced in prostate cancer and hence stop tumor spreading, whilst leaving other processes intact,” Dr. Harris remarked.

Dr. Harris and his team will perform tests on the re-engineered inhibitor in animals over the next months. "It feels like we have been covered in a shower of gold at the moment, it is very exciting for us because we are a small team but we have been working very hard on this for a long time,” he said. "We are extremely happy because now we can carry out trials in mouse-models of prostate cancer and if we have positive results, we could get a pharmaceutical industry partner interested in the work. "Currently bluebox, QUT's commercialization company, is helping us towards that goal. The dream end-product is having a drug which could be produced in sunflower seeds and given as a simple dietary supplement for people with prostate cancer.”


Related Links:
Queensland University of Technology

Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Online QC Software
Acusera 24•7
HPV Molecular Test
BD Onclarity HPV Assay
Benchtop Thermomixer
Biometra TS1 ThermoShaker
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The updated CRC screening guidance adds a stool RNA test and an updated stool DNA test to the menu of preferred options (image credit: Adobe Stock)

Updated Guidance Prioritizes Stool-Based Colorectal Cancer Screening Tests

Colorectal cancer is the second-leading cause of cancer death in the United States and claimed an estimated 55,000 lives in 2026. Incidence is rising among adults younger than 50, even as overall mortality... Read more

Immunology

view channel
Image: Study design for analysis of monocyte phenotype, function, and metabolism (Gráinne Jameson et al., Journal of Infection (2026). DOI: 10.1016/j.jinf.2026.106755)

Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response

Tuberculosis (TB) remains the world’s leading infectious killer, with 10.8 million cases and 1.25 million deaths recorded globally in 2023. Yet many infected individuals never develop active disease, underscoring... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.